It has been revealed that PD-1 or PD-L1 caused the death of T cells and the inhibitors of PD-1/PD-L1 showed higher efficacy and safety in various tumors, including renal cell cancer (RCC), lung cancer, and melanoma. Here, PDCD1 is linked to melanoma.